

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3914449

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	VIROBAY, INC.	02/24/2016
	CELERA CORPORATION	02/25/2016
RECEIVING PARTY DATA		
Name:	QUEST DIAGNOSTICS INVESTMENTS LLC	
Street Address:	3 GIRALDA FARMS	
City:	MADISON	
State/Country:	NEW JERSEY	
Postal Code:	07940	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	10603437
CORRESPONDENCE DATA		
Fax Number:	(202)672-5399	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2026725300	
Email:	apatrick@foley.com	
Correspondent Name:	KRISTEL SCHORR	
Address Line 1:	3000 K STREET, NW, SUITE 600	
Address Line 2:	FOLEY & LARDNER, LLP	
Address Line 4:	WASHINGTON, D.C. 20007-5109	
ATTORNEY DOCKET NUMBER:	034827-0715	
NAME OF SUBMITTER:	KRISTEL SCHORR	
SIGNATURE:	/Kristel Schorr/	
DATE SIGNED:	06/13/2016	
Total Attachments: 6		
source=090836-0715126_Schedule C(1)#page1.tif		
source=090836-0715126_Schedule C(1)#page2.tif		
source=090836-0715126_Schedule C(1)#page3.tif		
source=090836-0715126_Schedule C(1)#page4.tif		

source=090836-0715126_Schedule C(1)#page5.tif

source=090836-0715126_Schedule C(1)#page6.tif

ASSIGNMENT

This ASSIGNMENT is made from ViroBay, Inc. a corporation of the state of California (hereinafter "Assignor"), to Quest Diagnostics Investments LLC, a Delaware limited liability company, having a principal place of business at 3 Giralda Farms, Madison, New Jersey 07940 (hereinafter "Assignee").

WHEREAS, Assignor claims and warrants that it owns all rights, title and interest of every kind, nature or description in and to the patents and patent applications listed in Schedule B hereto;

WHEREAS, Celera Corporation, a Delaware Corporation ("Celera"), is an affiliate of Assignee; and

WHEREAS, Assignor and Assignee wish for Assignee to acquire all rights in the patents and patent applications listed in Schedule B hereto, for the convenience of the parties.

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor:

1. Has assigned, transferred, conveyed, and sold, and hereby assigns, transfers, conveys, and sells to Assignee all rights, titles and interests in and to:
 - (a) the Inventions throughout the world,
 - (b) all of the Patents, the right to claim priority to the Patents, and all U.S. and non-U.S. patents, registrations, validations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisions, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations of any of the Patents, all for the full term or terms for which the same may be granted (collectively, the "Patent Rights"); and
 - (c) all claims for damages by reason of past infringement of any of the Patent Rights (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use; and
2. Authorizes and requests the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue any and all of the Patent Rights to Assignee.
3. Agrees to sign, and procure signature of, all papers and documents, including without limitation, applications, declarations, oaths, assignments and petitions, and, at


ASSIGNMENT

Page 2 of 6


Assignee's expense, perform any other acts necessary in Assignee's reasonable opinion in connection with prosecution, maintenance or enforcement of any of the Patent Rights.


4. Agrees that the terms, covenants, and conditions of this Assignment shall inure to the benefit of Assignee, its successors, assigns and other legal representative, and shall be binding upon Assignor and its successors, legal representatives, and assigns.

Signed on the dates indicated beside our signatures.

ViroBay, Inc.
Signature:  Date: February 24th, 2016
Robert Booth, Ph.D.
Chief Executive Officer

Assignee and Celera hereby accept this Assignment.

Quest Diagnostics Investments LLC
Signature:  Date: 2/25/2016
Wayne Benjamin Brown
Deputy General Counsel & Chief Intellectual
Property Officer

Celera Corporation
Signature:  Date: 2/25/2016
Wayne Benjamin Brown
Deputy General Counsel & Chief Intellectual
Property Officer

68233159V.1

ASSIGNMENT

Page 3 of 6

Schedule C

Title IP Family Number	Country	Status	Serial No Filing Date	Patent No. Issue Date
AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739483 005010CA	Canada	Abandoned	2,526,694 June 4, 2004	
AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739484 005010EP	European Patent Office	Abandoned	04776274.5 June 4, 2004	
AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739485 005010JP	Japan	Abandoned	2006-515175 June 4, 2004	
COMBINATION THERAPY UTILIZING CATHEPSIN S INHIBITORS 090836-0739492 005110US	United States of America	Abandoned	10/581,977 Oct 19, 2006	
COMBINATION THERAPY UTILIZING CATHEPSIN S INHIBITORS 090836-0739489 005110EP	European Patent Office	Abandoned	04813839.0 Dec 10, 2004	
AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739494 005210EP	European Patent Office	Abandoned	04815518.8 Dec 22, 2004	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739260 005310US	United States of America	Abandoned	10/587,867 Dec 21, 2006	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739776 005310BR	Brazil	Abandoned	PI05064945 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739500 005310BY	Belarus	Abandoned	A20060865 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739139 005310CO	Colombia	Abandoned	06-085,611 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739140 005310CR	Costa Rica	Abandoned	8,754 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739141 005310EC	Ecuador	Abandoned	SP-06-6805 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739142 005310EP	European Patent Office	Abandoned	05722609.4 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739143 005310ID	Indonesia	Abandoned	W-00200602130 Jan 31, 2005	

ASSIGNMENT

Page 4 of 6

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739147 005310KR	Republic of Korea	Abandoned	10-2006-7017471 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739149 005310NO	Norway	Abandoned	20063842 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739152 005310PH	Philippines	Abandoned	1-2006-501469 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739258 005310SG	Singapore	Abandoned	200605107-2 Jan 31, 2005	
SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739259 005310UA	Ukraine	Abandoned	200600408 Jan 31, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739502 005610BR	Brazil	Abandoned	PI0515470-7 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739506 005610CO	Colombia	Abandoned	CO07026396 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739507 005610CR	Costa Rica	Abandoned	8993 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739508 005610CU	Cuba	Abandoned	2007-064 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739509 005610EC	Ecuador	Abandoned	SP-07-7321 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739510 005610EP	European Patent Office	Abandoned	05796693.9 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0746365 005610HK	Hong Kong	Abandoned	08100583.5 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739511 005610ID	Indonesia	Abandoned	W00200700899 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739515 005610KR	Republic of Korea	Abandoned	10-2007-7008584 Sep 16, 2005	

ASSIGNMENT

Page 5 of 6

PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739517 005610NO	Norway	Abandoned	20071937 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739522 005610SG	Singapore	Abandoned	200701879-9 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739523 005610UA	Ukraine	Abandoned	200704193 Sep 16, 2005	
PROCESSES AND INTERMEDIATES PREPARING CYSTEINE PROTEASE INHIBITORS 090836-0739525 005610ZA	South Africa	Abandoned	2007/03102 Sep 16, 2005	
HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739527 005810EP	European Patent Office	Abandoned	05852553.6 Dec 1, 2005	
SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739532 005901US	United States of America	Expired	60/664,123 Mar 21, 2005	
SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739777 005902US	United States of America	Expired	60/224,287 Mar 21, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739782 006110US	United States of America	Abandoned	11/662,931 Sep 16, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739780 006110BR	Brazil	Abandoned	PI1515449-9 Sep 16, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739539 006110EP	European Patent Office	Abandoned	05798153.2 Sep 16, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739542 006110KR	Republic of Korea	Abandoned	10-2007-7008656 Sep 16, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739544 006110NO	Norway	Abandoned	20071936 Sep 16, 2005	
POLYMORPHYS OF A CYSTEINE PROTEASE INHIBITOR 090836-0739783 006110ZA	South Africa	Abandoned	2007/03104 Sep 16, 2005	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739575 006300US	United States of America	Expired	60/664,041 Mar 21, 2005	

ASSIGNMENT

Page 6 of 6

ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739582 006310US	United States of America	Abandoned	11/909,047 Sep 18, 2007	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739581 006310PC	PCT	Expired	PCT/US06/10422 Mar 21, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739577 006310CA	Canada	Abandoned	2,603,305 Mar 21, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739578 006310EP	European Patent Office	Abandoned	06739282.9 Mar 21, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739579 006310JP	Japan	Abandoned	2008-503134 Mar 21, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739580 006310MX	Mexico	Abandoned	MX/a/2007/011615 Mar 21, 2006	
SULFONYL COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739584 006401US	United States of America	Expired	60/664,237 Mar 22, 2005	
SULFONYL COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0797435 006420US	United States of America	Abandoned	13/005,361 Jan 12, 2011	
HCV INHIBITORS 090836-0867414 006630EP	European Patent Office	Abandoned	13155117.8 Jun 29, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739550 006203US	United States of America	Expired	60/684,488 May 24, 2005	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0876056 006214US	United States of America	Abandoned	13/898,171 May 20, 2013	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739563 006210LV	Latvia	Abandoned	200720070121 Mar 17, 2006	13669 May 10, 2009
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0858719 006211EA	Eurasian Patent Office	Abandoned	201201550 Mar 17, 2006	
ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS 090836-0739561 006220JP	Japan	Abandoned	2012-142243 Mar 17, 2006	

PATENT

RECORDED: 06/13/2016

REEL: 038894 FRAME: 0537